DCAF13 inhibits the p53 signaling pathway by promoting p53 ubiquitination modification in lung adenocarcinoma

Table 2 Relationship between DCAF13 expression and clinicopathological characteristics

Group		Case(percent)		DCAF13 expression		p value^a
Group		Case(percent)		low	high	p value^a
gender n = 90	total	90		27	63
	female	36	(40.00%)	14	22	0.162
	male	54	(60.00%)	13	41
age n = 90	total	90		27	63
	≤ 55	23	(25.56%)	4	19	0.187
	>55	67	(74.44%)	23	44
grade n = 90	total	90		27	63
	1	7	(7.78%)	5	2	0.010
	2	55	(61.11%)	18	37
	3	28	(31.11%)	4	24
stage n = 89	total	89		27	62
	1	31	(34.83%)	11	20	0.797
	2	20	(22.47%)	6	14
	3	37	(41.57%)	10	27
	4	1	(1.12%)	0	1
T n = 86	total	86		26	60
	1	18	(20.93%)	5	13	0.894
	2	48	(55.81%)	16	32
	3	15	(17.44%)	4	11
	4	5	(5.81%)	1	4
N n = 77	total	77		22	55
	0	43	(55.84%)	13	30	0.487
	1	14	(18.18%)	5	9
	2	15	(19.48%)	2	13
	3	5	(6.49%)	2	3
EGFR n = 69	total	69		21	48
	negative	56	(81.16%)	19	37	0.317
	positive	13	(18.84%)	2	11
ALK n = 73	total	73		22	51
	negative	59	(80.82%)	20	39	0.204
	positive	14	(19.18%)	2	12

ISSN: 1756-9966